modelCalciumPhosphate
Extends from Pharmacolibrary.Drugs.ATC.A.A12AA01.
Information
| name: | CalciumPhosphate | |
| ATC code: | A12AA01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 0.007 | L/min |
| other parameters in model implementation | ||
Calcium phosphate is an inorganic mineral salt used as a calcium supplement in the treatment and prevention of calcium deficiency. It is utilized in various formulations (tribasic, dibasic, monobasic) for dietary supplementation, antacid, and as a pharmaceutical excipient. Not typically considered a drug with systemic pharmacological action, it is approved and widely used today as a supplement rather than a primary therapeutic agent.
Pharmacokinetics
No detailed pharmacokinetic model or parameter has been directly reported for calcium phosphate in humans, since its main function is to provide elemental calcium, which is absorbed via the gastrointestinal tract. The PK parameters below are estimated based on literature for oral calcium salts in healthy adults.
References
Hicks, J, et al., & Flaitz, C (2004). Biological factors in dental caries: role of remineralization and fluoride in the dynamic process of demineralization and remineralization (part 3). The Journal of clinical pediatric dentistry 28(3) 203–214. DOI:10.17796/jcpd.28.3.w0610427l746j34n PUBMED:https://pubmed.ncbi.nlm.nih.gov/15163148
Liu, Y, et al., & Hunziker, EB (2018). The kinetics and mechanism of bone morphogenetic protein 2 release from calcium phosphate-based implant-coatings. Journal of biomedical materials research. Part A 106(9) 2363–2371. DOI:10.1002/jbm.a.36398 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29569828
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)